Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 6

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]

Authors Kesayan T, Shaw J, Jones T, Staffetti J, Zesiewicz T

Received 10 August 2015

Accepted for publication 10 August 2015

Published 3 February 2016 Volume 2016:6 Pages 13—15

DOI https://doi.org/10.2147/DNND.S94117


Kesayan T, Shaw JD, Jones TM, Staffetti JS, Zesiewicz TA. Degenerative Neurological and Neuromuscular Disease 2015;5:63–72.

The authors would like to correct the following errors: on page 64; paragraph 1, “RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 6 mg/24 hours, with recommended titration of 2 mg/24 hours weekly.5 For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours.7” should be “RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 8 mg/24 hours (2–6 mg/24 hours in the US), with recommended titration of 2 mg/24 hours weekly.5 For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours (4–8 mg/24 hours in the US).5

View original article by Kesayan et al

On page 64; paragraph 5, “The mean RTG dose was 8 mg/24 hours, while the mean ropinirole dose was 14.1 mg/day.” should have been “The majority of patients (92%) received RTG maintenance dose of 8 mg/24 h, while the median ropinirole dose was 14.1 mg/day.”

On page 64; paragraph 6, “Three hundred and forty-one patients were randomized to receive RTG 8 mg/24 hours, 12 mg/24 hours, or placebo for 28 weeks.” should have been “Three hundred and forty-one patients were randomized to receive RTG up to 8 mg/24 hours, up to 12 mg/24 hours, or placebo for 28 weeks.”

On page 65; Table 1, data in the Doses column and the Notes section have been updated.

Table 1 Efficacy of RTG in early and advanced PD
Notes: aRTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information5), ie, 4.5 mg is equivalent to 2 mg/24 h, 9 mg to 4 mg/24 h, 13.5 mg to 6 mg/24 h, and 18 mg to 8 mg/24 h; bThe mean (SD) dose was 5.7 (0.84) mg/24 h; 6 mg dose for majority of participants; cNinety-two percent of those in the RTG group were treated with this dose in the maintenance phase and 8% had lower doses; there was no SD reported for UPDRS II or III separately; however, the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase (P<0.0001); dthere was no SD reported for UPDRS II or III separately, however the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase (P<0.0001).
Abbreviations: RTG, rotigotine; PD, Parkinson’s disease; UPDRS II, Unified Parkinson’s Disease Rating Scale part II (activities of daily living); UPDRS III, Unified Parkinson’s. Disease Rating Scale part III (motor examination); Plo, placebo.

On page 66; paragraph 2, “In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (<1.5 mg/day), or ropinirole (<6.0 mg/day), and RTG (<8 mg/24 hours) for an 8-week treatment period.7” should have been “In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (≤1.5 mg/day), or ropinirole (≤6.0 mg/day), and RTG (≤8 mg/24 hours) for an 8-week treatment period.7”

On page 68; Table 3, data in the Study, doses column for the Stiasny-Kolster study and the Notes section have been updated.

Table 3 Efficacy of RTG in RLS – change from baseline ± SD (P-value)
Notes: aA mean dose of RTG in the treatment group was reported as 2.1 mg/24 hours; bRTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information5), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h.
Abbreviations: RTG, rotigotine; RLS, restless legs syndrome; SD, standard deviation; IRLS, International Restless Legs Syndrome Study Group severity rating scale; CGI-1, Clinical Global Impressions item-1; PSQI, Pittsburgh Sleep Quality Index; Plo, placebo.

On page 69; Table 4, the data for the Stiasny–Kolster study and the Notes section have been updated.

Table 4 Side effects present in participants (%) during randomized, double–blinded, placebo–controlled trials
Notes: aThe study did not report the association of adverse events (AE) in relation to the dose of RTG. A mean dose of RTG in the treatment group was reported as 2.1 mg/24 hours; bRTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information5), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h.
Abbreviations: RTG, rotigotine; Plo, placebo.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]